Drugs / SAN021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02993328 | Jun 2018 → Jan 2019 | psoriasis | Santalis Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAN021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02993328 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Botanical Drug” NCT02993328 ↗ |
| Route | Topical | “Subjects will be instructed on how to apply the study medication twice daily for 42 days.” NCT02993328 ↗ |